MX380183B - Control de la formacion de enlaces disulfuro en disoluciones de proteinas mediante la adicion de agentes reductores. - Google Patents

Control de la formacion de enlaces disulfuro en disoluciones de proteinas mediante la adicion de agentes reductores.

Info

Publication number
MX380183B
MX380183B MX2016015615A MX2016015615A MX380183B MX 380183 B MX380183 B MX 380183B MX 2016015615 A MX2016015615 A MX 2016015615A MX 2016015615 A MX2016015615 A MX 2016015615A MX 380183 B MX380183 B MX 380183B
Authority
MX
Mexico
Prior art keywords
control
disulfide bond
reducing agents
bond formation
protein solutions
Prior art date
Application number
MX2016015615A
Other languages
English (en)
Other versions
MX2016015615A (es
Inventor
Christopher Hwang
Jin Yin
Kevin P Brower
Konstantin Konstantinov
Marcella Yu
Rao Koduri
Veena Warikoo
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2016015615A publication Critical patent/MX2016015615A/es
Publication of MX380183B publication Critical patent/MX380183B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a métodos que han sido desarrollados para controlar la formación de enlaces disulfuro entre polipéptidos de una proteína multimérica producida por un bioproceso. También se describen parámetros de disoluciones de proteínas que permiten controlar la formación de enlaces disulfuro. En un ejemplo, los métodos aquí descritos se pueden usar para controlar la proporción de moléculas de semianticuerpos en una disolución de anticuerpos.
MX2016015615A 2014-05-28 2015-05-28 Control de la formacion de enlaces disulfuro en disoluciones de proteinas mediante la adicion de agentes reductores. MX380183B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004175P 2014-05-28 2014-05-28
US14/668,820 US10647777B2 (en) 2014-05-28 2015-03-25 Methods of controlling the formation of disulfide bonds in protein solutions
PCT/US2015/033048 WO2015184183A1 (en) 2014-05-28 2015-05-28 Controlling the formation of disulfide bonds in protein solutions by adding reducing agents

Publications (2)

Publication Number Publication Date
MX2016015615A MX2016015615A (es) 2017-04-25
MX380183B true MX380183B (es) 2025-03-12

Family

ID=53396587

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015615A MX380183B (es) 2014-05-28 2015-05-28 Control de la formacion de enlaces disulfuro en disoluciones de proteinas mediante la adicion de agentes reductores.

Country Status (13)

Country Link
US (3) US10647777B2 (es)
EP (1) EP3149033B1 (es)
JP (2) JP6742919B2 (es)
KR (1) KR102457995B1 (es)
CN (1) CN107001407B (es)
AU (1) AU2015266860B2 (es)
CA (1) CA2950190C (es)
IL (1) IL249142B (es)
MX (1) MX380183B (es)
RU (2) RU2020115514A (es)
SG (2) SG11201609480UA (es)
TW (2) TWI736071B (es)
WO (1) WO2015184183A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3454890A4 (en) * 2016-05-10 2020-01-15 MedImmune, LLC PREVENTION OF PROTEIN DISULFIDE BOND REDUCTION
JP2020525445A (ja) * 2017-06-21 2020-08-27 セファロン・インコーポレイテッドＣｅｐｈａｌｏｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ カチオン交換クロマトグラフィーの洗浄緩衝液
TWI825066B (zh) * 2018-02-01 2023-12-11 美商再生元醫藥公司 治療性單株抗體之品質屬性的定量及模型化
US12240919B2 (en) 2019-03-26 2025-03-04 Kaneka Corporation Method for supporting thiol group-including compound
KR102370142B1 (ko) * 2020-03-23 2022-03-04 프레스티지바이오로직스 주식회사 항체 의약품 제조를 위한 배양 및 정제 공정의 하이브리드 시스템
EP4594462A1 (en) 2022-09-28 2025-08-06 Genzyme Corporation Systems and devices for producing biological products and methods of using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
TW517059B (en) * 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
EP1144452B1 (en) * 1998-11-03 2006-01-11 Centocor, Inc. Modified antibodies and antibody fragments with increased duration of activity
AU2005299716B2 (en) * 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
AU2008234248C1 (en) * 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
HUE046992T2 (hu) * 2007-07-09 2020-04-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
US20110086366A1 (en) 2008-02-22 2011-04-14 Genmab A/S Methods for assessing the risk of adverse events upon treatment with igg4 antibodies
US9150663B2 (en) * 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
CN102008732B (zh) 2010-11-08 2012-10-24 武汉华耀生物医药有限公司 一种叶酸偶联抗体药物及其制备方法与应用
TWI671315B (zh) 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2013055958A1 (en) * 2011-10-11 2013-04-18 Genentech, Inc. Improved assembly of bispecific antibodies
DK2771364T3 (da) * 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
EP2831089A1 (en) * 2012-03-30 2015-02-04 Krishnan, Archana Rajesh Process for renaturation of polypeptides

Also Published As

Publication number Publication date
IL249142A0 (en) 2017-01-31
SG11201609480UA (en) 2016-12-29
US20240392030A1 (en) 2024-11-28
EP3149033B1 (en) 2023-07-26
AU2015266860A1 (en) 2016-12-15
MX2016015615A (es) 2017-04-25
TW202031290A (zh) 2020-09-01
KR20170007457A (ko) 2017-01-18
JP7138135B2 (ja) 2022-09-15
AU2015266860B2 (en) 2021-01-28
RU2020115514A (ru) 2020-11-30
RU2016151320A3 (es) 2019-01-25
EP3149033A1 (en) 2017-04-05
US20160108127A1 (en) 2016-04-21
CN107001407B (zh) 2021-10-15
TWI736071B (zh) 2021-08-11
CA2950190C (en) 2023-01-17
CA2950190A1 (en) 2015-12-03
WO2015184183A1 (en) 2015-12-03
JP2017518293A (ja) 2017-07-06
RU2721592C2 (ru) 2020-05-20
JP2020124215A (ja) 2020-08-20
IL249142B (en) 2022-02-01
CN107001407A (zh) 2017-08-01
SG10201810634UA (en) 2018-12-28
RU2016151320A (ru) 2018-06-28
KR102457995B1 (ko) 2022-10-24
TWI707693B (zh) 2020-10-21
US10647777B2 (en) 2020-05-12
US20200299402A1 (en) 2020-09-24
JP6742919B2 (ja) 2020-08-19
TW201609134A (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CY1123236T1 (el) Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
MX375524B (es) Anticuerpos anti-axl.
EA202091598A2 (ru) Процесс контроля уровня содержания гликанов в составе
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
MX380183B (es) Control de la formacion de enlaces disulfuro en disoluciones de proteinas mediante la adicion de agentes reductores.
EA201791093A1 (ru) Антитела к cd47, способы и применение
HRP20181741T1 (hr) Postupci proizvodnje za kontrolu sadržaja c-terminalnog lizina, galaktoze i sijalinske kiseline u rekombiniranim proteinima
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
JOP20210010A1 (ar) بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
EA202092435A3 (ru) Моноклональные антитела против bcma
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
PE20170665A1 (es) Anticuerpos anti-tau humanizados
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
EA201892063A1 (ru) МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn
EA201690992A1 (ru) Антитела, специфичные к fcrn
MX2018016096A (es) Anticuerpos antagonistas de anti-axl.
ZA201703510B (en) Antibodies, uses & methods
EA201691532A1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
EA201690269A1 (ru) Способы контроля уровней фукозилирования в белках